← Back to patent-cliff list
Soquelitinib
Tier C — Watch / tradeSoquelitinib
Corvus Pharmaceuticals Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：ITK
Indications (approved)：T-cell lymphoma, Anaplastic large cell lymphoma, Peripheral T-cell lymphoma, 血管免疫母T细胞淋巴瘤, Eczema, Atopic dermatitis, 自身免疫性淋巴细胞增生综合征, Hidradenitis suppurativa
Regional status
US
Phase III
2024-10-02
EU
-
China
Phase II
2026-01-29
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Soquelitinib?
Approved indications include: T-cell lymphoma, Anaplastic large cell lymphoma, Peripheral T-cell lymphoma, 血管免疫母T细胞淋巴瘤, Eczema, Atopic dermatitis, 自身免疫性淋巴细胞增生综合征, Hidradenitis suppurativa.
When does the Soquelitinib patent expire?
No public expiry year is available for Soquelitinib yet; this page updates once verified.
How do I get a quote for Soquelitinib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01